一分钟看懂
这是一项关于晚期实体瘤的I 期研究，登记的药物或干预包括BGB-43395；Fulvestrant；Letrozole；Elacestrant；Anti-Diarrheal Agent，当前状态为招募中。登记地点显示中国北京、福州、广州、哈尔滨等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BGB-43395；Fulvestrant；Letrozole；Elacestrant；Anti-Diarrheal Agent · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital · 北京
- Fujian Cancer Hospital · 福州
- Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South) · 广州
- Harbin Medical University Cancer Hospital · 哈尔滨
- The First Affiliated Hospital of Nanchang University Branch Donghu · 南昌
- Liaoning Cancer Hospital and Institute · 沈阳
- Fudan University Shanghai Cancer Centerpudong · 上海
公开的入选条件
- * Phase 1a (Dose Escalation): Participants with histologically or cytologically confirmed advanced, metastatic, or unresectable solid tumors associated with dependency on CDK4, including HR+ breast cancer, ovarian cancer, endometrial cancer, non-small cell lun
- * Phase 1a Safety Expansion: For combination with fulvestrant in regions where approved and available, participants with HR+ breast cancer must have received at least 1 prior line of treatment including endocrine therapy and a CDK4/6 inhibitor. For combination
- * Phase 1b: Participants with HR+/HER2- breast cancer.
- * Phase 1b: For combination with fulvestrant, participants with HR+/HER2- breast cancer enrolled in regions where CDK4/6 inhibitors are approved and available must have received 1-2 lines of therapy for advanced/metastatic disease including endocrine therapy a
- * Stable Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1.
- * Female participants with metastatic HR+/HER2- breast cancer must be postmenopausal or receiving ovarian function suppression treatment.
- * Adequate organ function without symptomatic visceral disease.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06120283；登记信息更新于 2026-09-11。